Meanwhile, Wang et al. demonstrated that the combined administration of a TβRI inhibitor (SB431542) and a shRNA against SMAD2/3 procured a reduction in the ability of sphere-formation by CD51+ CRC cells, cell motility, and tumor formation [74]. This evidence concerns the gene SMAD2 and neoplasm.